As the race to expand a COVID-19 vaccine grows, it has been decided that Indiana University School of Medicine is one of 81 sites in the country to verify an experimental vaccine in patients.
Medical school announced Thursday morning that it will recruit up to 1,500 volunteers within 8 weeks to participate in a complex clinical trial of a vaccine developed through British drug manufacturer AstraZeneca in partnership with Oxford University.
Trials will be conducted at IU Health University Hospital, Indiana, for study only.Across the United States, researchers plan to enroll a total of 30,000 participants in this study.
AstraZeneca said it needs to manufacture tens of millions of doses until the end of this year’s vaccine, known as AZD1222, but before you can administer the doses to doctors and clinics, you will first need to perform full tests to see if the vaccine is effective.and get approval from the U.S. Food and Drug Administration.But it’s not the first time
AZD1222 is one of 4 vaccines in the complex testing phase for COVID-19 prevention in the United States.
The U.I. Medical School said Indiana citizens are invited to participate in the trials, however, volunteers will have to go to Indianapolis to get two doses of the vaccine or placebo, as well as to attend follow-up visits.time and participation.
Volunteer participants must be 18 years of age or older and should not have had a positive diagnosis of COVID-19, but will have to have a greater threat of COVID-19, such as running in a school, store, warehouse.or health care system, the medical school said.Those interested in participating in the exam can request updates by joining the All IN for Health Volunteer Registry.
“We have an ambitious goal, given the scope and scope of this study,” dr.Tatiana Foroud, Associate Dean of Research Affairs at the U.S. School of Medicine, in a written statement.”While many of the clinical trials we conduct recruit a fraction of what we expect in this case, we have the infrastructure in place to complete our research segment, adding valuable data on the prospective effectiveness of a vaccine in other people in Indiana.”
The selected volunteer participants will be a pattern of the demographics of the Indianapolis population.
“Our study team has developed partnerships considered over the years with minority teams in Indianapolis, with which we plan to have interaction at the beginning of the registration process,” dr.Cynthia Brown, who will lead the teams, rehearsals, in a written statement.”Almost 40% of the city’s population is made up of blacks, Hispanics or Asians, and we know how vital it is to have as many participants imaginable as we paint to find the most productive preventive remedy for this terrible pandemic.”
A team of scientists from the University of Oxford in England began developing AZD1222 in January.The effects of early-stage tests show that the vaccine produces T cells and antibodies, which are mixed for strong immune response.Immune responses were observed in participants who won two doses of the vaccine.
Allow javascript to view this content.